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Factors associated with breast cancer
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prediction of death using history of cancer
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Abstract
Background: In addition to tumor characteristics and lifestyle factors, cancer relapses are often related to the risk of
death but have not been jointly studied. We investigate the prognostic factors of recurrent events and death after a
diagnosis of breast cancer and predict individual deaths including a history of recurrences.
Methods: The E3N (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l’Education Nationale) study
is a prospective cohort study that was initiated in 1990 to investigate factors associated with the most common types of
cancer. Overall survival and three types of recurrent events were considered: locoregional recurrence, metastasis, and
second primary breast cancer. Recurrent events and death were analyzed using a joint frailty model.
Results: The analysis included 4926 women from the E3N cohort diagnosed with a first primary invasive breast cancer
between June 1990 and June 2008; during the follow-up, 1334 cases had a recurrence (median time of follow-up is 7.
2 years) and 469 women died. Cases with high grade, large tumor size, axillary nodal involvement, and negative estrogen
and progesterone receptors had a higher risk of recurrence or death. Furthermore, smoking increased the risk of relapse.
For cases with a medium risk profile in terms of tumor characteristics and lifestyle factors, the probability of dying between
5 and 10 years after diagnosis was 6, 20 and 36% for 0, 1 or 2 recurrences within the first 5 years after diagnosis, respectively.
Conclusions: Our study showed the importance of considering baseline lifestyle characteristics and history of relapses to
dynamically predict the risk of death in breast cancer cases. Medical experience coupled with an estimate of a patient’s
survival probability that considers all available information for this patient would enable physicians to make better informed
decisions regarding their actions and thus improve clinical output.
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Background
Breast cancer is the most common type of cancer in
women worldwide and the leading cause of cancer death
in women [1]. Between 8 and 10% of women diagnosed
with breast cancer will present locoregional recurrences
[2–4], and 15 to 30% will develop distant metastases [4].
Tumor characteristics are the main prognostic factors
for breast cancer outcome. A tumor size larger than 2 cm,
axillary nodal involvement, negative estrogen and proges-
terone receptors, and high grade have been shown to in-
crease the risk of death after breast cancer diagnosis and
the risk of locoregional recurrence and metastases [5].
Young age at diagnosis has also been associated with a
worse clinical outcome, partly because of the over-
representation of more aggressive subtypes in young cases
compared to older cases, such as triple negative or HER2-
positive breast cancer, or because of delayed diagnosis and
presentation at an advanced stage [6].
Lifestyle factors might also influence the risk of recur-
rence and/or death after breast cancer diagnosis. Excess
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weight, which is associated with a higher risk of post-
menopausal breast cancer, is also associated with a
higher risk of breast cancer recurrence and death [7].
Smoking is weakly associated with breast cancer risk [8]
but has been associated with a higher risk of death after
breast cancer, with a 60% higher risk in current smokers
at breast cancer diagnosis and a 50% risk in former
smokers of over 35 pack-years [9, 10]. Similar findings
have been reported for the risk of recurrence [10]. Alco-
hol intake, a risk factor for breast cancer, increases also
the risk of recurrence [11, 12]. However studies investi-
gating the interplay between alcohol and other important
lifestyle risk factors and certain disease characteristics as
well as genetic susceptibility are called for. In contrast, the
relation between alcohol consumption and breast cancer
survival is less clear [13].
Reproductive factors associated with breast cancer risk
could influence breast cancer survival: women with a diag-
nosis of breast cancer before menopause have a greater
risk of recurrence and death [3]. Although hormone
replacement therapy (HRT) has been found to increase
the risk of breast cancer in healthy women, pre-diagnostic
HRT use showed no effect or a decreased mortality in
most observational studies [14, 15]. Conversely, the
Women Health Initiative (WHI) trial noted that
mammary tumors diagnosed in the estrogen plus proges-
tin (E + P) treatment group had worse prognostic charac-
teristics compared to the placebo group [15].
Most studies on prognostic factors for breast cancer
recurrence were performed using Cox proportional haz-
ard models or competing-risks regression models [15].
In these studies, the follow-up of the patient ceased after
the first relapse, and subsequent recurrences were not
considered in the prediction of cancer-related death.
The successive relapses can be analyzed using a shared
frailty model for the recurrent events to account for the
intra-subject correlation. However, in many settings, a
joint modeling approach for time to recurrence and for
death is required. First, in relation to the recurrences,
given the strong relationship between recurrences and
breast cancer-related death [3], death should not be
considered an independent censoring process. Second,
in relation to death, the number of recurrences occur-
ring during follow-up should be considered a time-
dependent covariate; in this context, the Cox propor-
tional hazards model is not applicable because it
requires that the time-dependent covariates be external
(or exogenous), that is, their value at a specific time
point t is not affected by the occurrence of an event at a
previous time point [16].
To overcome these problems, Mauguen et al. [17] pro-
posed to apply a joint frailty model [18, 19], that
accounted both for the dependence between recurrences
and the dependence between recurrences and death.
They showed that when predicting the risk of death, ac-
counting for relapses led to better prediction
performance.
In this paper we applied a joint model to study the
effects of tumor characteristics, lifestyle characteristics
and reproductive factors on the risk of relapse and death
after a first invasive breast cancer diagnosis using inci-
dent cases within the population-based E3N cohort.
More specifically, we studied the dynamic prediction of
the risk of death considering baseline lifestyle character-
istics and history of recurrent events.
Methods
The E3N cohort
The E3N (Etude Epidémiologique auprès de Femmes de
la Mutuelle Générale de l’Education Nationale) study is
a prospective cohort study that was initiated in 1990 to
investigate factors associated with the most common
types of cancer [20]. It includes 98,995 women living in
France who were born between 1925 and 1950 and were
covered by a national health insurance plan that primar-
ily covers teachers. The participants complete biennial
self-administered follow-up questionnaires on health
status, medical history and lifestyle. All of the subjects
signed an informed consent form at study entry, and the
study protocol was approved by the French National
Commission for Computed Data and Individual Free-
dom. The E3N cohort is the French component of the
European Prospective Investigation into Cancer and
Nutrition (EPIC) and therefore the baseline question-
naire of E3N is based on the EPIC questionnaire.
Detailed information in English on the EPIC study is
available here: http://epic.iarc.fr/index.php.
Ascertainment of recurrent events and death after breast
cancer
The time-to-event was defined as the time between the
date of diagnosis of the first invasive breast cancer and
the date of each recurrent event or death. Three types of
recurrent events were considered: locoregional recur-
rence, metastasis, and second primary breast cancer. Pri-
mary cancers and recurrent events were self-reported to
the E3N team by the participants or their next-of-kin or
were identified among the causes of death on the death
certificate. The information was then validated via path-
ology reports or any other medical document. We then
considered the date of the medical record as the exact
date for the first breast cancer diagnosis and for the suc-
cessive recurrent events. The participants’ vital status
was regularly updated through the health insurance plan,
postal service, and next-of-kin; causes of death were
obtained from the French National Service on Causes of
Death. In this work we considered all-cause mortality
among breast cancer patients.
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Study population
The study population consisted of 5690 E3N women
who were diagnosed with invasive non-metastatic breast
cancer confirmed by medical records between June 1990
and June 2008. End of follow-up was defined as the date
of death, date of last response to a questionnaire (cen-
sored), date of diagnosis of a recurrent event, or June 25,
2008, whichever occurred first. Women with in situ
breast cancer (N= 735) or a metastatic breast cancer at
first diagnosis (N = 29) were not included.
Among eligible cases, 242 women declared one or sev-
eral recurrent events that were not confirmed and were
then censored at the date of the event. The type of re-
current event was missing for 9 additional women; these
events were removed and the women were censored at
the time of the event. Thirty-five women died of breast
cancer with metastases reported at death but not before.
These events were imputed 2 years before death for 18
women (mean time between all types of relapse and
death in this study) and 1 day before death for the others
because the delay between cancer and death was less
than 2 years.
Statistical analyses
Recurrent events such as locoregional recurrence,
metastasis, or second primary breast cancer may lead to
death; conversely, because death prevents any new
recurrent events, it is a competing event for recurrences,
and these two processes may be correlated. Joint frailty
models allow us to study the joint evolution over time of
two survival processes by considering all successive
recurrent events and the terminal event (death) [18, 19].
Prognostic factors considered are described in Tables 3
and 4 The characteristics of the first diagnosed tumor
were considered: estrogen and progesterone receptor
status, differentiation grade, tumor size, axillary nodal
involvement. We also considered at the time of diagno-
sis: age, history of benign breast disease, history of dia-
betes, history of breast cancer in first-degree relatives,
alcohol consumption and Body Mass Index (BMI). Other
characteristics included the level of education, smoking
status, menopausal status and use of menopausal hor-
monal treatment (MHT) in the year prior to the breast
cancer diagnosis. We also adjusted for the smoking sta-
tus after diagnosis because women may stop smoking
after breast cancer diagnosis. The year of breast cancer
diagnosis was used as a proxy for breast cancer care.
We proposed also a dynamic prediction tool to predict
the risk of death over a certain period of time, given the
history of relapses and the past history in terms of co-
variates for a patient. The estimated probability can be
updated following a new disease relapse. Different
scenarios were considered by varying the window of pre-
diction and the number and timing of recurrent events
as previously performed in Mauguen et al. [17]. Three
different profiles of patients according to risk factors
(low, medium and high risk profile) were considered.
The analytical framework for the model and this dy-
namic prediction is provided in the (see Additional file 1).
All of the analyses were performed using the Frailtypack
2.6 package of the R software [21, 22].
Results
During follow-up, among the 4926 cases of the study sam-
ple, 549 patients (11.2%) were lost to follow-up, 1334
recurrent events occurred including 343 locoregional
recurrences, 603 metastases, and 388 s primary breast
cancers; 18% of women suffered at least one recurrent
event, 12% suffered exactly one event, 4% suffered two
events and 2.1% suffered three or more) (see Table 1).
The median time between breast cancer and any recur-
rent event was 7.2 years (IQR: 3.9–11.2 years). The
median time between breast cancer diagnosis and the first
recurrence was 3.8 years for the first event, 5.9 years for
the second event, and 6.8 years for the third event. Locor-
egional recurrences generally occurred sooner after breast
cancer diagnosis (median = 3.9 years, IQR: 1.2–7.6) than
metastases (median = 4.8 years, IQR: 2.4–7.9) or second
primary breast cancers (median = 5.4 years, IQR: 2.8–8.5).
Most events occurring after the first event were metasta-
ses (185 subjects, see Table 2).
During follow-up, 469 women died. The median time
between breast cancer and death was 5.6 years (IQR:
3.3–8.9 years). For the women who died, the time be-
tween the last non-fatal recurrent event and death de-
creased with the increasing number of recurrent events.
In total, 4.4% of those with no recurrence, 20% of those
with one recurrence, 50% of those with two recurrences
Table 1 Statistical summary of number of events: N = 4926
No. % Time between first
cancer and event
median [IQR]
Number of recurrent events by woman
0 4040 82.0
1 604 12.3 3.8 [1.8–7.2]
2 180 3.7 5.9 [3.3–9.2]
3–7 102 2.1 6.8 [3.8–9.5]
Type of event
Local recurrence 343 25.7 3.9 [1.2–7.6]
Metastasis 603 45.2 4.8 [2.4–7.9]
Second primary breast cancer 388 29.1 5.4 [2.8–8.5]
All recurrences 1334 100.0 7.2 [3.9–11.2]
Death 469 9.5 5.6 [3.3–8.9]
IQR interquartile range
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and more than 70% of those with three or more recur-
rences died during follow-up.
We observed that 13% of the cases were double hor-
mone receptor negative; 40% were poorly differentiated;
19% had a tumor larger than 2 cm and 28% had nodal
involvement (see Table 3).
We observed that before the cancer diagnosis, 11% of the
women were current smokers (see Table 4). After the can-
cer diagnosis, only 6% of the women continued to smoke.
Table 5 presents the results of the multivariate joint frailty
model. Negative hormonal receptors, poorly differentiated
tumor, large tumor size and nodal involvement were all
associated with an increased risk of recurrent events and
death. The recent use of MHT was associated with a
decreased risk of recurrence (hazard ratio (HR) = 0.75, 95%
CI: 0.62, 0.92) but was not associated with the risk of death.
Smoking increased the risk of relapse (HR for current
smoker vs never smoker = 1.55, 95% CI: 1.16, 2.07). Breast
cancers diagnosed after 2000 were significantly less likely to
relapse than those diagnosed before. This result is likely
linked to the shorter follow-up time for those with a diagno-
sis after 2000 and thus a lower probability to observe recur-
rences. The risk of death was higher when breast cancer was
diagnosed after age 60 (HR = 4.50, 95% CI: 1.29, 15.78 for
60–70 vs < 50 years and HR= 9.08, 95% CI: 1.89, 43.69 for
70+ vs < 50 years). Menopausal status was not a significant
risk predictor.
The risk of death was strongly dependent on the history
of recurrence even after adjusting for the covariates (frailty
variance θ and power α significantly different from zero).
Dynamic prediction of the risk of death
Individual dynamic prediction of death was performed
on three profiles of risk factors identified on the basis of
Table 2 Mean time between two events in years and number of patients observed by type of event, until the 4th event (median
follow-up time = 7.2 years)
Cancer- 1st event 1st- 2nd event 2nd- 3rd event 3rd- 4th event TOTAL
End period event Year (σ) N (%) Year (σ) N (%) Year (σ) N (%) Year (σ) N (%) Year (σ) N (%)
Locoregional recurrence 4.1 276 3.4 47 1.8 6 2.2 7 4.9 343
(3.8) (5.6) (3.3) (5.3) (2.5) (2.1) (2.7) (7.1) (3.6) (5.5)
Metastasis 4.4 281 1.5 185 0.9 90 0.5 29 2.7 603
(3.5) (5.7) (2.2) (21.0) (1.3) (32.4) (0.9) (29.6) (3.2) (9.6)
Second primary breast cancer 5.6 329 3.4 50 2.6 6 2.3 2 5.3 388
(4.1) (6.6) (3.4) (5.7) (3.6) (2.1) (3.1) (2.0) (4.0) (6.2)
Death 5.3 179 2.5 128 1.9 91 1.3 44 3.3 469
(3.3) (3.6) (2.3) (14.6) (1.9) (32.9) (1.4) (44.9) (3.0) (7.5)
Censored 7.4 3861 5.1 464 3.3 84 2.3 16 7.1 4436
(4.7) (78.4) (3.9) (53.1) (2.9) (30.3) (2.7) (16.3) (4.7) (71.1)
TOTAL 7.0 4926 3.8 874 2.0 277 1.3 98 6.1 6239
(4.7) (100%) (3.6) (100%) (2.3) (100%) (1.8) (100%) (4.7) (100%)
σ = standard error
Table 3 Breast cancer characteristics of study population, N= 4926
No. of women Percentage
Estrogen/Progesterone receptors Status
positive / positive 2321 47.1
positive / negative 770 15.6
negative / positive 161 3.2
negative / negative 636 12.9
missing 1038 21.1
Grade
well differentiated 650 13.2
moderately differentiated 1517 30.8
poorly differentiated 1965 39.9
missing 794 16.1
Tumor size
< 2 cm 3694 74.0
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Age at breast cancer diagnosis
< 50 years 647 13.1
[50–60) years 2145 43.5
[60–70) years 1712 34.8
≥ 70 years 422 8.6
Menopausal status at breast cancer diagnosis
postmenopausal woman - more than 5 years of
cumulated MHT use
1144 23.2
postmenopausal woman - less than 5 years of
cumulated MHT use
1205 24.5
postmenopausal woman - no use of MHT 1314 26.7
premenopausal woman 923 18.7
Missing 340 6.9




Smoking status before diagnosis
never smoker 2624 53.3
current smoker 562 11.4
ex-smoker 1717 34.9
missing 23 0.5
Smoking status at first follow-up after diagnosis
never smoker 2624 53.3
current smoker 314 6.4
ex-smoker 1664 33.8
missing 324 6,6





History of benign breast disease before diagnosis
Yes 2575 52.3
No 2351 47.7
History of diabetes before diagnosis
Yes 258 5.2
No 4668 94.8
Level of education before diagnosis
< high school level 568 11.5
high school level-second year university level 2351 47.7
> second year university level 1803 36.6
Missing 204 4.1





underweight (< 18.5) 132 2.7
normal (18.5- < 25) 3255 66.1





overweight (25- < 30) 1073 21.8
obese (≥ 30) 264 5.3
Missing 202 4.1
MHT menopausal hormonal treatment, BMI Body Mass Index
Table 5 Joint model estimation on population (N = 2708, 632
recurrent events, 212 deaths)
Variables (% of women) Recurrent event Overall death
HR 95% CI HR 95% CI
Estrogen/Progesterone receptor status
+/− vs +/+ (18.6%) 1.40 1.10, 1.79 2.51 1.20, 5.30
−/+ vs +/+ (4.1%) 1.00 0.62, 1.59 5.63 1.55, 20.46




1.61 1.15, 2.27 3.12 0.99, 9.91
poorly differentiated vs well
differentiated (48.5%)
1.90 1.36, 2.66 6.54 2.02, 21.18
Tumor size (≥ 2 cm vs < 2 cm)
(20.5%)
1.64 1.33, 2.01 4.70 2.27, 9.75
Axillary nodal involvement
(yes vs no) (30.0%)
1.54 1.26, 1.86 5.23 2.63, 10.42
Recent MHT use before diagnosis
(yes vs no) (44.3%)
0.75 0.62, 0.92
Smoking status first follow-up
after diagnosis
ex-smoker vs never smoker
(36.9%)
1.20 1.00, 1.44




1995–1999 vs 1990–1994 (28.9%) 0.90 0.72, 1.13
2000–2003 vs 1990–1994 (32.3%) 0.72 0.56,0.94
2004–2008 vs 1990–1994 (27.4%) 0.61 0.43, 0.89
Age at breast cancer diagnosis (year)
[50–60) vs < 50 (44.1%) 1.80 0.68, 4.79
[60–70) vs < 50 (38.0%) 4.50 1.29, 15.78
≥ 70 vs < 50 (9.5%) 9.08 1.89,43.69
Menopausal status at breast cancer diagnosis
postmenopausal woman - no use of MHT
vs premenopausal woman (27.1%)
1.39 0.58, 3.32
postmenopausal woman-less than 5 years




5 years of cumulated MHT use vs
premenopausal woman (28.8%)
0.35 0.11, 1.10
θ 1.01 (σ = 0.05) p-value< 0.001
α 4.29 (σ = 0.77) p-value< 0.001
HR hazard ratio, σ standard error, 95% CI 95% Confidence Interval, MHT
menopausal hormonal treatment
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the previous results: a low, medium, high-risk profile
(see Fig. 1). When the history of recurrent events was
not considered (P2), the probability of death was overes-
timated if no recurrent events were diagnosed and
underestimated if recurrent events occurred.
The number of recurrent events greatly affected the
risk of death: for the medium risk profile, the probability
of death (P1) between 5 and 10 years after cancer diag-
nosis was 6% (95% CI: 1, 16) for no recurrence in the
first 5 years after diagnosis, 19% (95% CI: 2, 37) for one
recurrence, 36% (95% CI: 5, 56) for two recurrences and
53% (95% CI: 11, 70) three previous recurrences;
between 5 and 15 years, the risk of death was 13% (95%
CI: 3, 28) if no recurrent events occurred and 36% (95%
CI: 10, 57), 59% (95% CI: 23, 78) and 76% (95% CI; 38,
89) if one, two or three events occurred, respectively.
The risk of death was also affected by risk factors: after two
recurrent events, the risk of death between 5 and 10 years
after the cancer diagnosis was 7, 36 and 51% in women
with low-, medium-, and high-risk profiles, respectively.
To estimate whether the predictions are accurate,
error of prediction curves based on the brier score were
used. Prediction errors (not presented here) were influ-
enced by the number and timing of relapses. Indeed,
with a Cox model, the prediction error of the risk of
death between 5 and 10 years was 9%, whereas in the
joint frailty model, which accounts for relapse times, the
prediction error was 8% with probability P2 and 7% with
probability P1.
Discussion
In this article, we studied jointly the prognostic factors for
successive relapses and death on a large cohort of women
with a primary breast cancer. We proposed a dynamic
individual prediction of the risk of death after breast cancer
using a history of cancer recurrences, tumor characteristics,
Fig. 1 Individual predicted probabilities of death for 3 patient profiles, with or without a history of relapses using joint frailty models. P1: probability of
death considering exactly J recurrent events, P2: probability of death not considering the history of recurrent events. Low-risk profile: Estrogen/
Progesterone receptor status = +/+, Grade = 1, Tumor size≤2 cm, Axillary nodal involvement = no, recent MHT use before diagnosis = yes, Smoking
status = never smoker, Year of diagnosis = 2004–2008, Age at breast cancer diagnosis≤50 years, Menopausal status = postmenopausal woman - less
than 5 years of cumulated MHT use. Medium-risk profile: Estrogen/Progesterone receptor status = +/−, Grade = 2, Tumor size≥2 cm, Axillary nodal
involvement = no, recent MHT use before diagnosis = yes, Smoking status = ex-smoker, Year of diagnosis = 1995–1999, Age at breast cancer diagnosis
= [50–60) years, Menopausal status = premenopausal woman. High-risk profile: Estrogen/Progesterone receptor status = −/−, Grade = 3–4, Tumor
size≥2 cm, Axillary nodal involvement = yes, recent MHT use before diagnosis = no, Smoking status = smoker, Year of diagnosis = 1990–1994, Age at
breast cancer diagnosis≥70 years, Menopausal status = postmenopausal woman - no use of MHT
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lifestyle characteristics and reproductive factors, showing
that at a given time after diagnosis, the risk of death was
strongly dependent on the number of relapses.
To date, relatively few studies have attempted to study
this association. Our results confirm the relevance of the
association between established prognostic factors, MTH
and cigarette smoking and the risk of recurrent events or
death after breast cancer. The association between lifetime
cigarette smoking and risk of breast cancer recurrence has
been previously described into the literature [10]. The
tumor characteristics (high grade, high tumor size, nodal
involvement) were also associated with a higher risk of
those two failure times, as previously shown by Mauguen
et al. [17]. Conversely, the risk of relapses or death was
lower for tumors with positive estrogen or progesterone
receptors [23]. We observed as in previous observational
studies [24], a lower risk of relapse for postmenopausal
women who had used MHT before breast cancer diagno-
sis. However, women on MHT undergo more frequent
mammographic monitoring and thus have an earlier can-
cer diagnosis [15]. Therefore, the observed better progno-
sis in terms of relapses for women using MHT in our
study is possibly biased. However, we adjusted for the
mammographic monitoring as a binary time dependent
covariate (with at least one mammographic visit before
the time of interest or without mammography). This vari-
able was non-significantly associated with both the risk of
recurrence (HR = 1.25, 95% CI: 0.98, 1.59) and the risk of
death (HR = 0.62, 95% CI: 0.27, 1.46). Furthermore, this
adjustment did not change the effect of the MHT use.
Menopausal status (with or without history of MHT use)
was not significant in the joint frailty model, even if the
same tendencies were observed with the use of MHT.
Smoking exposure after breast cancer diagnosis was
associated with an increased risk of relapse but not with
the risk of death. This might be explained by the fact
that almost half of the smokers stopped smoking after
their cancer diagnosis. Obesity, a factor that has been
previously associated with the risk of recurrence and
death after breast cancer [7], was not significant in our
study. However, E3N women are relatively slim (less
than 6% were obese at breast cancer diagnosis), which
might have resulted in a limited power to detect an asso-
ciation in this subgroup. Our study did not confirm any
association of alcohol consumption or education level
and the risk of recurrences or death. The year of breast
cancer diagnosis was used as a proxy for breast cancer
care. We did not obtain a significant association with
this year of diagnosis and the risk death however the risk
of recurrence was significantly lower after 2000. This
might probably be explained by three reasons. Due to
the design of the cohort, the breast cancer diagnosed in
the 1990’ties will have longer follow-up than breast can-
cer diagnosed more recently. We also completed these
results by a sensitivity analysis on the same sample but
more homogeneous in terms of follow-up durations. In
this new sample, the follow-up of the subjects was trun-
cated at 10 years and those with a follow-up greater than
10 years were censored at 10 years. The results, on these
patients with shorter follow-up times showed really simi-
lar findings, with the same association on the risk of re-
currence and on death. Furthermore the introduction of
Trastuzamab (Herceptin) in 1998 for the adjuvant treat-
ment of Her2+ breast cancer has significantly reduced
relapse rates. Finally since 2004 in France, there is a
countryside breast cancer screening program for women
aged 50–74. This recent screening program is associated
with breast cancers diagnosed earlier and at an earlier
stage. This can also explain the reduction of recurrence
rates with time. However adjusting also for the mam-
mography monitoring as a binary time dependent
covariate did not change the associations.
A major limitation of this study is the absence of vari-
ables describing the cancer treatments. The year of
breast cancer diagnosis, in combination with tumor
characteristics, can be viewed as a proxy variable linked
to the treatment evolution. The results reflect a lower
risk of relapses for those recently diagnosed who are
likely using aromatase inhibitors and practicing the tech-
nique of sentinel lymph node. However, for patients di-
agnosed after 1999, the follow-up time is shorter and the
probability of observing a relapse is consequently lower.
We have illustrated that some specific profiles of breast
cancer patients vary according to tumor characteristics,
lifestyle characteristics, reproductive factors and the his-
tory of relapses; these factors may predict different prob-
abilities of dying in the future. The proposed approach
was able to show that the number of relapses greatly af-
fects the predicted risk of death and that better predic-
tions of death are obtained by considering the history of
relapses rather than only considering prognostic factors.
For example, the “naïve” probability of death that does not
consider the history of relapses was overestimated. Using
this individual dynamic prediction tool, we illustrated that
death probabilities must be updated each time additional
relapses are recorded. In our analysis, we did not consider
time-dependent covariates, such as modifications in the
patient’s treatment, BMI, smoking habits or MHT use.
However, similar to how these time-dependent covariates
are allowed in the joint modeling, they are allowed in the
prediction calculation. Although all of the analyses were
performed using a standard statistical R package, a level of
expertise in programming may be required. An easy web
application as Adjuvant Online [25] could provide the
opportunity for every physician to derive updated
predictions for new patients when history of relapses or
more outcomes (such as longitudinal biomarkers) are
available, as in Krol et al. [26].
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Conclusion
In conclusion, survival outcomes after a breast cancer
are affected by the occurrence of relapses, and the pro-
posed approach (with joint model) is really appropriate
to both study their link and to predict the prognosis of
patients suffering from a primary breast cancer and with
possible relapses. These dynamic prediction tools would
be valuable in everyday medical practice. That is, med-
ical experience coupled with an estimate of a patient’s
survival probability that considers all available informa-
tion for this patient would enable physicians to make
better informed decisions regarding their actions and
patient care and thus improve clinical output.
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